生物制剂防治造血干细胞移植致口腔黏膜炎的研究进展

doi:10.13701/j.cnki.kqyxyj.2023.07.004

口腔医学研究 ›› 2023, Vol. 39 ›› Issue (7): 582-585.DOI: 10.13701/j.cnki.kqyxyj.2023.07.004

生物制剂防治造血干细胞移植致口腔黏膜炎的研究进展

郭锦材^1,3,4, 张树生^2,3*

1.长沙市口腔医院药剂科湖南长沙 410006;
2.长沙市口腔医院湖南长沙 410006;
3.湖南中医药大学口腔医学院湖南长沙 410006;
4.湖南中医药大学药学院湖南长沙 410208

收稿日期:2022-07-04 发布日期:2023-07-25
通讯作者: *张树生,E-mail: 2680329408@qq.com
作者简介:郭锦材(1987~ ),男,湖南桂东人,硕士,副主任药师,研究方向:口腔循证医学。
基金资助:
湖南省重点领域研发计划(编号:2020SK2137);湖南省自然科学基金(编号:2021JJ70062);长沙市自然科学基金(编号:kq2014019);湖南省医学会医学科研基金临床药学项目( 编号:HMA202001012);湖南省保健委专项资金科研课题(编号:B2020-07)

Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

GUO Jincai^1,3,4, ZHANG Shusheng^2,3*

1. Department of Pharmacy, Changsha Stomatological Hospital, Changsha 410006, China;
2. Changsha Stomatological Hospital, Changsha 410006, China;
3. School of Stomatology, Hunan University of Chinese Medicine, Changsha 410006, China;
4. School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China

Received:2022-07-04 Published:2023-07-25

摘要/Abstract

摘要： 造血干细胞移植(hematopoietic stem cell transplantation,HSCT)是血液恶性肿瘤重要的治疗方式之一,但该治疗方法常致口腔黏膜炎(oral mucositis, OM)。造血干细胞移植致口腔黏膜炎(HSCT-OM)发生率高,临床治疗棘手。近几年有较多生物制剂探索性应用于HSCT-OM的治疗,部分生物制剂治疗效果较好。本文对防治HSCT-OM生物制剂的临床研究做一综述,为HSCT-OM的临床防治和研究提供参考。

关键词: 造血干细胞移植, 口腔黏膜炎, 生物制剂

Abstract: Hematopoietic stem cell transplantation (HSCT) is one of the most important treatment modalities for hematologic malignancies, but this treatment often causes oral mucositis (OM). The incidence of OM caused by HSCT (HSCT-OM) is high and the clinical treatment is difficult. Many biologic agents have been used exploratively in the treatment of HSCT-OM and some are effective. This paper reviews the clinical studies of biologic agents, and provides a reference for the clinical prevention and treatment of HSCT-OM.

Key words: hematopoietic stem cell transplantation, oral mucositis, biological agents

郭锦材, 张树生. 生物制剂防治造血干细胞移植致口腔黏膜炎的研究进展[J]. 口腔医学研究, 2023, 39(7): 582-585.

GUO Jincai, ZHANG Shusheng. Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation[J]. Journal of Oral Science Research, 2023, 39(7): 582-585.

参考文献

[1] Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: A systematic review [J]. Biol Blood Marrow Transplant, 2016, 22(4):605-616.
[2] da Silva BM, Prosdócimo ML, Gasparini LR, et al. Most used photobiomodulation dosimetry parameters to treat oral mucositis after preconditioning for hematopoietic stem cell transplantation: systematic review and meta-analysis [J]. Support Care Cancer, 2022, 30(5):3721-3732.
[3] Costa ALF, Santos BA, Torregrossa VR, et al. Oral shedding of CMV and HSV-1 in hematopoietic stem cell transplantation patients [J]. Oral Dis, 2021, 27(6):1572-1579.
[4] Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers [J]. N Engl J Med, 2004, 351(25):2590-2598.
[5] Coutsouvelis J, Corallo C, Spencer A, et al. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy [J]. Crit Rev Oncol Hematol, 2022, 172:103606.
[6] Raber-Durlacher JE, Von Bültzingslöwen I, Logan RM, et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients [J]. Support Care Cancer, 2013, 21(1):343-355.
[7] Stiff PJ, Leinonen M, Kullenberg T, et al. Long-term safety outcomes in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation treated with palifermin to prevent oral mucositis [J]. Biol Blood Marrow Transplant, 2016, 22(1):164-169.
[8] Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results [J]. Biol Blood Marrow Transplant, 2007, 13(7):806-813.
[9] Logan RM, Al-Azri AR, Bossi P, et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines [J]. Support Care Cancer, 2020, 28(5):2485-2498.
[10] Patel P, Robinson PD, Baggott C, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update [J]. Eur J Cancer, 2021, 154:92-101.
[11] Alqahtani SS, Khan SD. Management of oral mucositis in children [J]. Eur Rev Med Pharmacol Sci, 2022, 26(5):1648-1657.
[12] Dazzi C, Cariello A, Giovanis P, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study [J]. Ann Oncol, 2003, 14(4):559-563.
[13] Van der Lelie H, Thomas BL, Van Oers RH, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study [J]. Ann Hematol, 2001, 80(3):150-154.
[14] Gordon B, Spadinger A, Hodges E, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation [J]. J Clin Oncol, 1994, 12(9):1917-1922.
[15] Kim KI, Kim JW, Lee HJ, et al. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation [J]. Am J Hematol, 2013, 88(2):107-112.
[16] Kim JW, Kim MG, Lee HJ, et al. Topical recombinant human epidermal growth factor for oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation: Final analysis of a randomized, double-blind, placebo-controlled, phase 2 trial [J]. PLoS One, 2017, 12(1):e0168854.
[17] Berglund S, Watz E, Remberger M, et al. Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation [J]. Vox Sang, 2019, 114(7):769-777.
[18] Piccin A, Rebulla P, Pupella S, et al. Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel [J]. Transfusion, 2017, 57(9):2220-2224.
[19] Ruggiero T, Pol R, Camisassa D, et al. Use of sodium hyaluronate and synthetic amino acid precursors of collagen for the symptomatic treatment of mucositis in patients undergoing haematopoietic stem cell transplants [J]. J Biol Regul Homeost Agents, 2016, 30(3):889-894.
[20] Ruggiero T, Pol R, Camisassa D, et al. Treatment of symptomatic oral mucositis with sodium hyaluronate and synthetic amino acid precursors of collagen in patients undergoing haematopoietic stem cell transplantation [J]. J Biol Regul Homeost Agents, 2018, 32(3):737-743.
[21] Giles FJ, Rodriguez R, Weisdorf D, et al. A phase Ⅲ, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy [J]. Leuk Res, 2004, 28(6):559-565.
[22] Hosseinjani H, Hadjibabaie M, Gholami K, et al. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial [J]. Hematol Oncol, 2017, 35(1):106-112.
[23] Ohbayashi Y, Imataki O, Uemura M, et al. Oral microorganisms and bloodstream infection in allogeneic hematopoietic stem cell transplantation [J]. Clin Oral Investig, 2021, 25(7):4359-4367.
[24] Elting LS, Chang YC. Costs of oral complications of cancer therapies: Estimates and a blueprint for future study [J]. J Natl Cancer Inst Monogr, 2019, 2019(53):lgz010.
[25] Shouval R, Kouniavski E, Fein J, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation [J].Eur J Haematol, 2019, 103(4):402-409.
[26] Curra M, Baldin J. Investigation of oral and general health status and IL-1β gene polymorphism as risk factors for oral mucositis in hematopoietic stem cell transplantation patients [J]. Braz Oral Res, 2022, 36:e016.
[27] Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation [J]. BMJ Support Palliat Care, 2017, 7(1):7-16.

生物制剂防治造血干细胞移植致口腔黏膜炎的研究进展

Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	王知刚, 张波. 重组人表皮生长因子外用溶液联合重组人粒细胞刺激因子治疗化疗所致口腔黏膜炎的效果[J]. 口腔医学研究, 2022, 38(1): 80-84.
[2]	王文梅, 段宁. EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展[J]. 口腔医学研究, 2021, 37(10): 869-874.
[3]	李庆福, 李锡清, 姜丽, 马欣. 化疗诱发口腔黏膜炎的危险因素分析[J]. 口腔医学研究, 2019, 35(8): 810-813.
[4]	周雨曦, 陶人川, 江巧芝. Smads蛋白在口腔慢性移植物抗宿主病患者血浆中的表达[J]. 口腔医学研究, 2019, 35(7): 666-670.